2550 Stanwell Drive
384 articles with Cerus Corporation
Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader
Cerus Corporation announced complete financial results for the fourth quarter and year ended December 31, 2019.
U.S. Department of Defense Awards Funding for Study to Evaluate the Use of INTERCEPT Plasma in Traumatic Burn Resuscitation
Cerus Corporation (Nasdaq: CERS) today announced a collaboration with the National Trauma Institute (NTI) to supply INTERCEPT plasma for use in the Plasma Resuscitation Without Lung Injury (PROpOLIs) clinical study.
Cerus Corporation (Nasdaq: CERS) announced today the pricing of a registered underwritten public offering of its common stock for proceeds of approximately $55.0 million, before deducting estimated offering expenses payable by Cerus.
Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a registered underwritten public offering of $50.0 million of its common stock
Coronavirus Inactivation Reported in Recent INTERCEPT Blood System Publication in Transfusion Medicine
Cerus Corporation (Nasdaq:CERS) today announced the publication of a study in Transfusion Medicine1 on the inactivation of the MERS (Middle Eastern Respiratory Syndrome) coronavirus in human platelet concentrates using the INTERCEPT Blood System for platelets.
French Hemovigilance Report Highlights Safety and Effectiveness of INTERCEPT Platelets During First Full Year of 100% Production and Routine Use
Cerus Corporation (Nasdaq:CERS) is pleased to announce the recent publication of the 16th Annual Hemovigilance report by the French National Agency for Medicines and Health Products (ANSM) which oversees the safety of medicine and other health products.
Company provides 2020 product revenue guidance range of $89 million to $93 million representing growth of approximately 20% to 25% over preliminary 2019 full year results
Cerus Corporation Announces New Five-Year INTERCEPT Blood System Agreement With Swiss Transfusion SRC
Cerus Corporation (Nasdaq:CERS) announced today that it has signed a new five-year commercial contract with Swiss Transfusion SRC, a company of the Swiss Red Cross, for purchase of the INTERCEPT Blood System.
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m. ET in New York City.
Cerus Corporation (Nasdaq:CERS) announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m. CT.
Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2019.
Cerus Corporation (Nasdaq:CERS) announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19th through October 22nd.
Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
Cerus Corporation applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry.
Cerus Corporation announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer will present and provide a corporate update at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019 at 3:00 p.m. ET.
Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in two upcoming investor conferences.
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2019.
The company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation Announces Presentations Highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
This year, the meeting is being held in Basel, Switzerland from June 22nd to June 26th.